Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

 

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 

 

Press Releases
24-Jun-20

U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas

Innate Pharma to re-activate TELLOMAK trial in the US New GMP-certified batch has been successfully manufactured Conference call to be held today on the lacutamab clinical trial program  Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today

20-May-20

Outcome of Annual General Meeting of May 19, 2020

Pascale Boissel appointed new member of Innate’s Supervisory    Board Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announces the results of the vote of its shareholders at the Annual General Meeting (“AGM”) which took place on May 19,

14-May-20

Innate Pharma to Present New Efficacy Data For Monalizumab in Combination With Cetuximab in Head And Neck cancer at The ASCO20 Virtual Scientific Progral

Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it